Hepatitis B, Non-Alcoholic Fatty Liver Disease, Vaccine Reaction
Conditions
Brief summary
(1) Due to missed childhood vaccination programs, the majority of adult patients with NAFLD in Canada do not have immunity to hepatitis B. (2) Adults with NAFLD who receive the HBV vaccine have reduced immunogenic responses in the setting of obesity (i.e., protective anti-HBs titres). Aims: (1) To determine the sero-prevalence of immunity against hepatitis B in a cohort of prospectively evaluated adult NAFLD patients. (2) To prospectively determine HBV vaccine responses (anti-HBs titres) in adult NAFLD patients.
Detailed description
The hepatitis B virus (HBV) is truly a global human pathogen that affects at least 2 billion people worldwide including \ 240 million chronic hepatitis B (CHB) carriers that are at risk for end-stage liver disease. The diagnosis of CHB is confirmed by the persistence of the HBV surface antigen (HBsAg) in serum for \>6 months. However, a latent form of HBV infection known as occult hepatitis B infection (OBI) characterized by low-level viremia (i.e., HBV DNA \< 200 IU/ml) despite undetectable serum HBsAg has been described with unclear clinical consequences. A safe and effective HBV vaccine has been available for \ 3 decades and consists of recombinant HBsAg which contains the major viral antigenic epitopes and induces a protective neutralizing antibody to HBsAg (anti-HBs) response in \>85% of children vaccinated. Canada is a low HBV-endemic region and in Alberta, and Ontario, public health uses maternal screening for HBsAg to identify babies at-risk for CHB. Thus, all infants born to HBsAg (+) mothers are given passive-active immunoprophylaxis with hepatitis B immune globulin (HBIG) and the HBV vaccine within 12 hours of birth, as well as 2 doses at \ 2 and \ 6 months of age. Testing of the infants for anti-HBs is recommended at 9 months to ensure immunity. In the late 1990's, a universal HBV childhood vaccination program was initiated in all Canadian provinces and jurisdictions. In Alberta and in Ontario, school-age children are scheduled to receive the 3-dose HBV vaccine series in grade 5. However there remain a significant proportion of adult Canadians (i.e., born before 1985) who missed childhood vaccination programs. Although current guidelines recommend that certain high-risk populations receive hepatitis B immunization, appropriate identification and compliance is generally much lower in adults compared to children. According to the most recent Canadian Association for the Study of Liver Disease guidelines, all adults with diabetes, as well as all patients with chronic liver disease should receive the hepatitis B vaccine. The basis for these recommendations are two-fold, (1) diabetics may be at risk of blood-borne virus (BBV) exposure through contact with contaminated blood glucose monitoring devices and (2) diabetic patients are at increased risk of the metabolic syndrome and the development of non-alcoholic fatty liver disease (NAFLD). The improvement in blood glucose monitoring devices, and increased knowledge has reduced the risk of HBV exposure in patients with diabetes. Further, the investigators' initial seroepidemiological survey of acute HBV outbreaks in Alberta revealed a decreasing prevalence in diabetic patients. Therefore the main incentive for HBV vaccination in diabetics is due to the concomitant risk of the metabolic syndrome and advanced liver disease due to NAFLD. There is limited data on HBV vaccination in NAFLD patients. Further studies are required in a North American adult (Canadian population). The investigators propose that adults with NAFLD should undergo comprehensive screening for hepatitis B immunogenicity, in addition to screening for infection, and catch up or booster vaccinations should be administered to non-immunized patients with confirmatory immunity testing thereafter.
Interventions
BIOLOGICALEngerix-B
Hepatitis B Vaccine
Sponsors
Canadian Institutes of Health Research (CIHR)
GlaxoSmithKline
University of Calgary
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Subjects 18-60 years of age, who provide signed informed consent * Diagnosis of NAFLD/NASH according to expert assessment (by imaging, TE, abnormal lab tests and/or liver biopsy) * No evidence of prior infection or immunity to hepatitis B (negative HBsAg, anti-HBs, anti-HBc).
Exclusion criteria
* Subjects \< 18 years of age, * Subjects who refused vaccination * Have documented immunity / prior exposure to hepatitis B (i.e., positive for ant-HBs, anti-HBc, HBsAg) * Pregnancy * HIV-positive * Decompensated cirrhosis (i.e., Child-Pugh Class B or C) due to impact on immune response. * Subjects \>60 y will be excluded, due to effect of age and reduced response to HBV vaccination.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Anti-HBs Titres (IU/L) | 1 month after completion of the vaccine series | to determine how NAFLD-associated metabolic risk factors and liver inflammation / fibrosis affects vaccine response |
| Assessment of Memory T Cells and HBsAg-specific-proliferation of CD3 + CD4+ TH Cells | 1 month after completion of the vaccine series | to determine how NAFLD-associated metabolic risk factors and liver inflammation / fibrosis affects vaccine response. Fresh (or cryopreserved in 4 patients) PBMC (\ 106) were labeled with 1 μM carboxyfluorescein-diacetate-succinimidyl-ester. Labeled PBMC were stimulated with 5 μg HBsAg) in RPMI 1640 with 10% FBS and 2mmol/L glutamine. Anti-CD3 (1 μg/mL) and anti-CD28 (5 μg/mL) stimulated cells served as a positive control. Unstimulated DMSO-treated cells were used as negative controls. Cells were cultured in triplicates and plates incubated at 37 °C with 5% CO2 for \ 8 days. Cell proliferation was assessed on day 8. SI was calculated as % CFSE low cells in stimulated cells / % CFSE low cells in the unstimulated control46. SI\> 3 was considered positive for HBsAg-specific proliferation. Cells were stained using the memory T-cell panel and analyzed by flow-cytometry |
Countries
Canada
Participant flow
Recruitment details
Patients with non-alcoholic fatty liver disease (NAFLD), without prior exposure to hepatitis B or hepatitis B vaccine. Recruitment period was August 2016-March 2020.
Pre-assignment details
No significant events were noted. 7 patients were lost to follow-up.
Participants by arm
| Arm | Count |
|---|---|
| HBV Vaccine Cohort Of 82 participants, all received the HBV vaccine. Vaccines were not blinded as patients were followed as standard of care. | 82 |
| Total | 82 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Lost to Follow-up | 7 |
Baseline characteristics
| Characteristic | HBV Vaccine Cohort |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 0 Participants |
| Age, Categorical Between 18 and 65 years | 82 Participants |
| Age, Continuous | 48.5 years STANDARD_DEVIATION 8.7 |
| BMI (body mass index) | 33.6 kg/m^2 STANDARD_DEVIATION 6.1 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 81 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Region of Enrollment Canada | 82 participants |
| Sex: Female, Male Female | 40 Participants |
| Sex: Female, Male Male | 42 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 82 |
| other Total, other adverse events | 0 / 82 |
| serious Total, serious adverse events | 0 / 82 |
Outcome results
Primary
Anti-HBs Titres (IU/L)
to determine how NAFLD-associated metabolic risk factors and liver inflammation / fibrosis affects vaccine response
Time frame: 1 month after completion of the vaccine series
Population: Anti-HBs levels were compared between two groups: low and high-risk obesity patients with NAFLD.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| BMI < 35 | Anti-HBs Titres (IU/L) | 642 Anti-HBS IU/L | Standard Deviation 68.2 |
| BMI > 35 | Anti-HBs Titres (IU/L) | 385 Anti-HBS IU/L | Standard Deviation 79 |
p-value: 0.02Wilcoxon (Mann-Whitney)
Primary
Assessment of Memory T Cells and HBsAg-specific-proliferation of CD3 + CD4+ TH Cells
to determine how NAFLD-associated metabolic risk factors and liver inflammation / fibrosis affects vaccine response. Fresh (or cryopreserved in 4 patients) PBMC (\ 106) were labeled with 1 μM carboxyfluorescein-diacetate-succinimidyl-ester. Labeled PBMC were stimulated with 5 μg HBsAg) in RPMI 1640 with 10% FBS and 2mmol/L glutamine. Anti-CD3 (1 μg/mL) and anti-CD28 (5 μg/mL) stimulated cells served as a positive control. Unstimulated DMSO-treated cells were used as negative controls. Cells were cultured in triplicates and plates incubated at 37 °C with 5% CO2 for \ 8 days. Cell proliferation was assessed on day 8. SI was calculated as % CFSE low cells in stimulated cells / % CFSE low cells in the unstimulated control46. SI\> 3 was considered positive for HBsAg-specific proliferation. Cells were stained using the memory T-cell panel and analyzed by flow-cytometry
Time frame: 1 month after completion of the vaccine series
Population: 17 patients with BMI \< 35 and 14 patients with BMI \> 35 for PBMC analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| BMI < 35 | Assessment of Memory T Cells and HBsAg-specific-proliferation of CD3 + CD4+ TH Cells | 5.1 Stimulation index | Standard Deviation 0.68 |
| BMI > 35 | Assessment of Memory T Cells and HBsAg-specific-proliferation of CD3 + CD4+ TH Cells | 3.1 Stimulation index | Standard Deviation 0.62 |